Join Growin Stock Community!
Beta
Back to PFE.US Analysis

Ticker

Value

empty

There is no following symbol in this watchlist.

  • EPS
  • EPS Diluted
  • Revenue
  • Operation Income
  • Net Income
  • Operating Expenses
  • Cash Flow
  • Cash & Debt
  • Current Contract Liabilities
eps-chart

PFE EPS

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

The latest data point for Pfizer's (PFE) EPS in Q1'26 stands at 0.47 USD, reflecting a modest positive figure following a negative Q4'25 result of -0.29 USD. This marks a slight recovery in earnings per share, though it remains below the peak of 0.79 USD observed in Q3'24. Over the period from Q2'23 to Q1'26, EPS exhibits high volatility with an initial decline into negative territory (reaching -0.59 USD in Q4'23), followed by a rebound to positive values averaging around 0.40 USD from Q1'24 onward, punctuated by occasional dips such as 0.01 USD in Q2'24 and -0.29 USD in Q4'25. Year-over-year EPS growth shows erratic patterns, with sharp improvements like +288% in Q3'24 and +50% in Q2'25 contrasting against steep declines such as -167% in Q4'23 and -514% in Q4'25, indicating underlying operational challenges and recoveries in the pharmaceutical sector. Overall, the trend suggests stabilization at low positive levels but with persistent fluctuations that warrant monitoring for sustained profitability.